Salbutamol

Pharmacologic Category

Beta₂ Agonist

Dosing: Adult

Note: In the United States, the metered-dose inhaler (MDI) and dry powder inhaler (DPI) formulations provide 90 mcg/actuation. In Canada, the MDI, Airomir [Canadian product], provides 100 mcg/actuation and the DPI, Ventolin Diskus [Canadian product], provides 200 mcg/actuation. Dosing is based on US products, unless otherwise noted. A valved holding chamber (spacer) is recommended for use with an MDI. A DPI does not require use of a valved holding chamber.

Oral formulations of albuterol (eg, tablet, syrup) are not advised as they are less effective for bronchoconstriction than inhaled forms and more likely to cause adrenergic adverse effects (GINA 2019; GOLD 2018).

Asthma:

Acute symptom relief: Note: Use on an as-needed basis rather than regularly scheduled. For patients with persistent asthma, additional agents should be used for maintenance (GINA 2019; Lemanske 2019a; Peters 2020; Wenzel 2019).

Inhalation: Note: Nebulized therapy may be preferable for patients who have more severe symptoms or who cannot effectively use an inhaler (Lemanske 2019b).

MDI or DPI (90 mcg/actuation): 2 inhalations every 4 to 6 hours as needed (Fanta 2019c); some experts recommend up to 4 inhalations every 4 to 6 hours for moderate to severe symptoms (Peters 2020; Wenzel 2019).

Canadian formulation: Ventolin Diskus [Canadian product]: DPI (200 mcg/inhalation): 1 inhalation every 4 to 6 hours as needed.

Nebulization solution: 2.5 mg every 4 to 6 hours as needed (Lemanske 2019b).

Acute exacerbation:

Mild to moderate exacerbations (initial home management): Note: Patients with worsening symptoms despite initial care should seek immediate medical attention.

Inhalation:

MDI or DPI (90 mcg/actuation): 2 to 4 inhalations every 20 minutes for 3 doses; if good response, can lengthen interval to every 3 to 4 hours as needed (Fanta 2019a).

Nebulization solution: 2.5 mg every 20 minutes for 3 doses; if good response, can lengthen interval to every 3 to 4 hours as needed (Fanta 2019a).

Moderate to severe exacerbations (management in primary or acute care settings): Note: For severe exacerbations, albuterol is used in combination with an inhaled short-acting muscarinic antagonist, and nebulized treatments are generally preferred (Hess 2019).

Inhalation:

MDI or DPI (90 mcg/actuation): 4 to 8 inhalations every 20 minutes for 3 doses, then taper as tolerated (eg, to 2 to 4 inhalations every 1 to 4 hours as needed) (Fanta 2019b). For extremely severe exacerbations, some experts suggest up to 10 inhalations for the initial doses (GINA 2019). High doses are typically administered in a monitored setting.

Nebulization solution: 2.5 to 5 mg every 20 minutes for 3 doses, then taper as tolerated (eg, to 2.5 to 5 mg every 1 to 4 hours as needed). For critically ill patients, 10 to 15 mg may be administered by continuous nebulization over 1 hour via special apparatus (Fanta 2019b).

IV continuous infusion [Canadian product]: Note: Reserve intravenous beta-agonists for those patients in whom inhaled therapy cannot be used reliably (BTS 2019). Initial: 5 mcg/minute; may increase up to 10 to 20 mcg/minute at 15- to 30-minute intervals, if needed.

Exercise-induced bronchoconstriction (prevention):

Inhalation:

MDI or DPI (90 mcg/actuation): 2 inhalations 5 to 20 minutes prior to exercise (ATS [Parsons 2013]; Bonini 2013; O’Byrne 2020).

Canadian formulation: Ventolin Diskus [Canadian product]: DPI (200 mcg/inhalation): 1 inhalation 15 minutes prior to exercise.

Bronchospasm (moderate to severe) due to anaphylaxis (adjunct to epinephrine): Note: Administer epinephrine first when treating anaphylaxis; administer albuterol for residual respiratory symptoms not responding to epinephrine. Do not use albuterol for initial or sole treatment of anaphylaxis because albuterol does not prevent or relieve upper airway edema, hypotension, or shock (AAAI [Lieberman 2015]; WAO [Simons 2011]).

Inhalation:

MDI or DPI (90 mcg/actuation): 2 to 3 inhalations as needed for symptom relief (Grammer 2020; Kang 2019).

Nebulization solution: 2.5 to 5 mg; repeat as needed (AAAI [Lieberman 2015]; Campbell 2019; WAO [Simons 2011]).

Chronic obstructive pulmonary disease:

Acute symptom relief: Note: Use on an as-needed basis rather than regularly scheduled. In patients who have moderate to severe symptoms or who are at high risk of exacerbation, additional agents should be used for maintenance therapy (GOLD 2018; Ferguson 2019). May be used in combination with an inhaled short-acting muscarinic antagonist (ATS/ERS [Celli 2004]; COMBIVENT Inhalation Aerosol Study Group 1994; GOLD 2018; Levin 1996).

Inhalation:

MDI or DPI (90 mcg/actuation): 2 inhalations every 4 to 6 hours as needed (Lee 2013).

Canadian formulation: Ventolin Diskus [Canadian product]: DPI (200 mcg/inhalation): 1 inhalation every 4 to 6 hours as needed.

Nebulization solution: 2.5 mg every 4 to 6 hours as needed (Nair 2005).

Acute exacerbation: Note: Optimal dosing not well-defined. Adjust dose according to clinical symptom resolution and tolerability (GOLD 2018; Nair 2005; Stoller 2019). May be combined with an inhaled short-acting muscarinic antagonist (GOLD 2018; Stoller 2019). Although similar efficacy exists among formulations, some experts prefer nebulized therapy during severe chronic obstructive pulmonary disease exacerbations (Stoller 2019).

Inhalation:

MDI or DPI (90 mcg/actuation): 1 to 2 inhalations every 1 to 4 hours as needed (GOLD 2018; Stoller 2019). If used for more severe exacerbations, can use 4 to 8 inhalations every 1 to 4 hours as needed (Stoller 2019).

Nebulization solution: 2.5 mg every 1 to 4 hours as needed (Nair 2005; Stoller 2019).

Hyperkalemia (alternative agent) (adjunct) (off-label use): Note: May use after administration of standard therapies (calcium, insulin with dextrose, and potassium removal therapy) for those with continued symptoms or serious ECG manifestations or in patients for whom dialysis is not appropriate or feasible (Mount 2019).

Inhalation: Nebulization solution: 10 to 20 mg via nebulization over 10 minutes (Allon 1989; Allon 1990; Kim 1997; Putcha 2007).

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Inhalation: Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; use with caution. No dosage adjustment required in patients on hemodialysis, peritoneal dialysis, or CRRT (Aronoff 2007).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Pediatric

Asthma, acute exacerbation: Note: GINA guideline dosing is based on the 100 mcg/actuation salbutamol product (not available in US) (GINA 2018)

Outpatient (mild to moderate exacerbations):

Infants and Children ≤5 years:

Metered-dose inhaler: 90 mcg/actuation: Oral inhalation: 2 to 6 inhalations every 20 minutes for 2 to 3 doses (GINA 2018; NAEPP 2007); if initial response to 2 doses is good, administer 2 to 6 inhalations every 3 to 4 hours for 24 to 48 hours (NAEPP 2007); some experts suggest that if there is rapid response to initial therapy and no symptoms recur after 1 to 2 hours, therapy can be changed to every 3 to 4 hours as needed (GINA 2018); if initial response is good, but recurs after 3 to 4 hours, administer 2 to 3 inhalations every hour with close monitoring (GINA 2018).

Nebulization: 2.5 mg every 20 minutes for the first hour if needed; if there is rapid response to initial therapy after 1 to 2 hours, therapy can be changed to every 3 to 4 hours as needed (GINA 2018)

Children ≥6 years and Adolescents: Metered-dose inhaler: 90 mcg/actuation: Oral inhalation: 2 to 10 inhalations every 20 minutes for 2 to 3 doses during the first hour (GINA 2018; NAEPP 2007); if initial response to 2 doses is good, administer 2 to 6 inhalations every 3 to 4 hours for 24 to 48 hours (NAEPP 2007); some experts suggest that if there is rapid response to initial therapy and no symptoms recur after 1 to 2 hours, therapy can be changed to every 3 to 4 hours as needed (GINA 2018); if initial response is insufficient, reported doses after the first hour may vary from 4 to 10 inhalations every 3 to 4 hours up to 6 to 10 inhalations every 1 to 2 hours (GINA 2018)

Emergency care/hospital:

Infants and Children:

Metered-dose inhaler: 90 mcg/actuation: Oral inhalation: Limited data available in ages <4 years: 4 to 8 puffs every 20 minutes for 3 doses then every 1 to 4 hours (GINA 2018; NAEPP 2007).

Nebulization: Limited data in ages <2 years:

Intermittent: 0.15 mg/kg/dose (minimum dose: 2.5 mg/dose) every 20 minutes for 3 doses then 0.15 to 0.3 mg/kg/dose not to exceed 10 mg/dose every 1 to 4 hours (NAEPP 2007)

Continuous nebulization: Dosing regimens variable; optimal dosage not established:

Weight based:

NIH Guidelines: 0.5 mg/kg/hour (NAEPP 2007)

Alternate dosing: Limited data available: 0.3 mg/kg/hour has been used safely in the treatment of severe status asthmaticus in children (Papo 1993); higher doses of 3 mg/kg/hour ± 2.2 mg/kg/hour in children (n=19, mean age: 20.7 months ± 38 months) resulted in no cardiotoxicity (Katz 1993)

Fixed dose (Krebs 2013): Limited data available:

<20 kg: 10 mg/hour

≥20 kg: 20 mg/hour

Note: Dosing based on a retrospective, observational chart review evaluating standard protocol dosing (n=373) and historical dosing (n=393); study showed the continuous nebulized albuterol to be safe, but not superior to historical physician driven dosing (Krebs 2013).

Adolescents:

Metered-dose inhaler: 90 mcg/actuation: Oral inhalation: 4 to 8 puffs every 20 minutes for up to 4 hours, then every 1 to 4 hours (NAEPP 2007)

Nebulization:

NIH Guidelines (NAEPP 2007):

Intermittent: 2.5 to 5 mg every 20 minutes for 3 doses then 2.5 to 10 mg every 1 to 4 hours as needed

Continuous: 10 to 15 mg/hour

Alternate dosing (Krebs 2013): Limited data available:

<20 kg: 10 mg/hour

≥20 kg: 20 mg/hour

Note: Dosing based on a retrospective, observational chart review evaluating standard protocol dosing (n=373) and historical dosing (n=393); study showed the continuous nebulized albuterol to be safe, but not superior to historical physician driven dosing (Krebs 2013).

Asthma, maintenance therapy (nonacute) (NAEPP 2007): Oral inhalation:

Metered-dose inhaler: Infants, Children, and Adolescents: Limited data available in ages <4 years: 90 mcg/actuation: Oral inhalation: 2 inhalations every 4 to 6 hours as needed. Note: Not recommended for long-term daily maintenance treatment; regular use exceeding 2 days/week for symptom control (not prevention of exercise-induced bronchospasm) indicates the need for additional long-term control therapy.

Nebulization:

Infants and Children <5 years (limited data in ages <2 years): Oral inhalation: 0.63 to 2.5 mg every 4 to 6 hours as needed

Children ≥5 years and Adolescents: Oral inhalation: 1.25 to 5 mg every 4 to 8 hours as needed

Bronchospasm:

Metered-dose inhaler: Oral inhalation:

90 mcg/actuation: Children ≥4 years and Adolescents: 1 to 2 inhalations every 4 to 6 hours

100 mcg/actuation: Airomir [Canadian product]:

Children 6 to 11 years:

Acute treatment: 1 inhalation; additional inhalations may be necessary every 4 to 6 hours as needed if inadequate relief; however, patients should be advised to promptly consult health care provider or seek medical attention if no relief from acute treatment (additional inhalations or more frequent administration is not recommended)

Maintenance (in combination with corticosteroid therapy): 1 inhalation every 4 to 6 hours as needed; maximum daily dose: 4 inhalations/day

Children ≥12 years and Adolescents:

Acute treatment: 1 to 2 inhalations; additional inhalations may be necessary every 4 to 6 hours as needed if inadequate relief; however, patients should be advised to promptly consult health care provider or seek medical attention if no relief from acute treatment (additional inhalations or more frequent administration is not recommended)

Maintenance (in combination with corticosteroid therapy): 1 to 2 inhalations every 4 to 6 hours as needed; maximum daily dose: 8 inhalation/day

Dry powder inhaler: Oral inhalation:

90 mcg/inhalation: Children ≥4 years and Adolescents: 1 to 2 inhalations every 4 to 6 hours

200 mcg/inhalation: Ventolin Diskus [Canadian product]: Children ≥4 years and Adolescents:

Acute treatment: 1 inhalation as needed; maximum daily dose: 4 inhalations/day; patient should be advised to promptly consult health care provider or seek medical attention if prior dose fails to provide adequate relief or if control of symptoms lasts <3 hours

Maintenance (in combination with corticosteroid therapy): 1 inhalation every 4 to 6 hours; maximum daily dose: 4 inhalations/day

Nebulization: Oral inhalation:

Children ≥2 years and Adolescents:

10 to 15 kg: 1.25 mg 3 to 4 times daily

>15 kg: 2.5 mg 3 to 4 times daily

Oral: Note: Not the preferred route for treatment of asthma; inhalation via nebulization or MDI is preferred (GINA 2018; NAEPP 2007)

Immediate-release formulation (syrup, tablets):

Children 2 to 6 years: 0.1 mg/kg/dose (maximum dose: 2 mg/dose) 3 times daily; if desired response not achieved, gradually increase dose to 0.2 mg/kg/dose (maximum dose: 4 mg/dose) 3 times daily

Children >6 and Adolescents ≤14 years: 2 mg/dose 3 to 4 times daily; if desired response not achieved, gradually increase dose; maximum daily dose: 24 mg/day

Adolescents >14 years: 2 to 4 mg/dose 3 to 4 times daily; if desired response not achieved, gradually increase dose; maximum daily dose: 32 mg/day

Sustained-release formulation (tablets):

Children ≥6 years: 4 mg every 12 hours; if control not achieved may gradually increase dose; maximum daily dose: 24 mg/day

Adolescents: 8 mg every 12 hours; some patients achieve control with 4 mg every 12 hours; if control not achieved may gradually increase dose; maximum daily dose: 32 mg/day

Exercise-induced bronchospasm; prevention:

Metered-dose inhaler: Oral Inhalation:

90 mcg/actuation (AAAAI/ACAAI [Weiler 2016]; ATS [Parsons 2013]; NAEPP 2007): Limited data available in ages <4 years:

Infants and Children <5 years: 1 to 2 inhalations 5 to 20 minutes before exercising

Children ≥5 years and Adolescents: 2 inhalations 5 to 20 minutes before exercising

100 mcg/actuation: Airomir [Canadian product]:

Children 6 to 11 years: 1 inhalation 30 minutes prior to exercise

Children ≥12 years and Adolescents: 2 inhalations 30 minutes prior to exercise

Dry powder inhaler: 200 mcg/inhalation: Ventolin Diskus [Canadian product]: Oral Inhalation: Children ≥4 years and Adolescents: 1 inhalation 15 minutes before exercise

Hyperkalemia; adjunct therapy: Note: Albuterol should not be used as the sole agent for treating severe hyperkalemia, especially in patients with renal failure (McClure 1994). Limited data available: Nebulization: Oral inhalation:

Weight-based dose: Infants, Children, and Adolescents: 0.3 to 0.5 mg/kg/dose administered as a rapid nebulization or via continuous nebulization (Fuhrman 2011)

Fixed dose (McClure 1994): Children ≥5 years and Adolescents:

<25 kg: 2.5 mg nebulized over 10 minutes; dose may be repeated in 2 hours if necessary

≥25 kg: 5 mg nebulized over 10 minutes; dose may be repeated in 2 hours if necessary

Note: Doses as high as 10 mg or 20 mg have been suggested for use in adults (Weiner 1998; Weisberg 2008).

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; use with caution when using high doses in patients with renal impairment. No dosage adjustment required, including patients on hemodialysis, peritoneal dialysis, or CRRT (Aronoff 2007).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling.

Use: Labeled Indications

Bronchospasm: Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease.

Exercise-induced bronchospasm: Prevention of exercise-induced bronchospasm.

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Hyperkalemia (inhalation)Level of Evidence [A, G]

Data from small controlled trials and a systematic review support the use of nebulized albuterol in the treatment of hyperkalemia ^Ref.

Based on American Heart Association evidence-based guidelines, nebulized albuterol is recommended as adjuvant therapy for acute treatment of moderate to severe hyperkalemia ^Ref. Access Full Off-Label Monograph

Level of Evidence Definitions

Level of Evidence Scale

Class and Related Monographs

Sympathomimetics

Clinical Practice Guidelines

Asthma:

British Thoracic Society, "British Guideline on the Management of Asthma," 2019 Update

Global Strategy for Asthma Management and Prevention (GINA), 2019 Update

NHLBI and NAEPP The Expert Panel Report 3: “Guidelines for the Diagnosis and Management of Asthma,” Full Report 2007

COPD:

ACCP/CTS, “Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: American College of Chest Physicians and Canadian Thoracic Society Guideline,” 2014

Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease, 2007 Update

GOLD 2018 Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2018

Exercise-induced Bronchoconstriction:

AAAAI and ACAAI, “Exercise-induced Bronchoconstriction,” Update - 2016

Administration: IV

Infusion solution [Canadian product]: Do not inject undiluted. Reduce concentration by at least 50% before infusing. Administer as a continuous infusion via infusion pump.

Administration: Oral

Do not crush or chew extended release tablets.

Administration: Inhalation

Dry powder inhalers:

ProAir Digihaler, ProAir RespiClick: Inhaler device is breath-actuated; does not require priming. Do not use with spacer or volume holding chamber. Keep inhaler clean and dry by wiping with dry cloth or tissue as needed; do not wash or put any part of inhaler in water.

Ventolin Diskus [Canadian product]: For oral inhalation route only. To activate Diskus, patient should slide lever using the thumb grip away from them as far as it will go (click should be heard). Before inhaling the dose, breathe out fully; do not exhale into the Diskus device. Bring mouthpiece to lips and inhale steadily and deeply through the Diskus; hold breath for about 10 seconds or for as long as comfortable and exhale slowly. To close Diskus slide thumb grip back as far as it will go towards its original position. To prevent a wasted dose, the lever should not be manipulated until administration of next dose. Diskus counts down from 60 to 1 and when 5 doses remain the numbers appear in red. Diskus should be kept dry.

Metered-dose inhalers: Shake well before use; prime prior to first use, and whenever inhaler has not been used for >2 weeks or when it has been dropped, by releasing 3 to 4 test sprays into the air (away from face). Airomir Canadian product labeling recommends releasing a minimum of 4 test sprays when priming. HFA inhalers should be cleaned with warm water at least once per week; allow to air dry completely prior to use. A spacer device or valved holding chamber is recommended for use with metered-dose inhalers.

Nebulization solution: Concentrated solution should be diluted prior to use; adjust nebulizer flow to deliver dosage over 5 to 15 minutes; avoid contact of the dropper tip (multidose bottle) with any surface, including the nebulizer reservoir and associated ventilator equipment. Blow-by administration is not recommended; use a mask device if patient unable to hold mouthpiece in mouth for administration.

Administration: Pediatric

Oral inhalation: In infants and children <4 years, a face mask with either the metered-dose inhaler or nebulizer is recommended (GINA 2018; NAEPP 2007)

Inhalation, aerosol: Metered-dose inhaler: Shake well before use; prime the inhaler prior to first use and whenever it has not been used for >2 weeks or when it has been dropped by releasing 3 to 4 test sprays into the air away from the face. Use spacer for children <5 years of age and consider adding a face mask for infants and children <4 years of age (GINA 2018). HFA inhalers should be cleaned with warm water at least once per week; allow to air dry completely prior to use.

Inhalation, powder: Dry powder inhaler: Inhaler device is breath-actuated; does not require priming. Do not use with spacer or volume holding chamber. Keep inhaler clean and dry by wiping with dry cloth or tissue as needed; do not wash or put any part of inhaler in water.

Nebulization: Concentrated solutions (≥0.5%) should be diluted prior to use; adjust nebulizer flow to deliver dosage over 5 to 15 minutes; avoid contact of the dropper tip (multidose bottle) with any surface, including the nebulizer reservoir and associated ventilator equipment. For continuous nebulization, the total amount of fluid delivered is determined by nebulizer delivery device; usually 25 to 30 mL per 1 hour of nebulization, protocols may vary by institution (Hegenbarth 2008). Blow-by administration is not recommended; use a mask device if patient is unable to hold mouthpiece in mouth for administration.

Oral: Do not crush or chew extended-release tablets.

Storage/Stability

Metered-dose inhalers (HFA aerosols): Store at 15°C to 25°C (59°F to 77°F). Do not store at temperature >120°F. Do not puncture. Do not use or store near heat or open flame.

Proventil HFA: Store with mouthpiece down.

Ventolin HFA: Discard when counter reads 000 or 12 months after removal from protective pouch, whichever comes first. Store with mouthpiece down.

Dry powder inhalers:

ProAir Digihaler, ProAir RespiClick: Store between 15°C and 25°C (59°F and 77°F). Avoid exposure to extreme heat, cold, or humidity. Discard 13 months after opening the foil pouch, or when the counter displays 0, whichever comes first.

Ventolin Diskus [Canadian product]: Store at ≤30°C (86°F). Keep in a dry place. Protect from frost and light. Diskus is nonrefillable and should be discarded after all doses have been administered.

Infusion solution [Canadian product]: Ventolin IV: Store at 15°C to 30°C (59°F to 86°F). Protect from light. After dilution, discard unused portion after 24 hours.

Nebulization solution: Store at 2°C to 25°C (36°F to 77°F). Do not use if solution changes color or becomes cloudy. Products packaged in foil should be used within 1 week (or according to the manufacturer's recommendations) if removed from foil pouch.

Syrup: Store at 20°C to 25°C (68°F to 77°F).

Tablet: Store at 20°C to 25°C (68°F to 77°F).

Tablet, extended release: Store at 20°C to 25°C (68°F to 77°F).

Preparation for Administration: Adult

Nebulization solution: 0.5% solution: Dilute 0.25 mL (1.25 mg dose) or 0.5 mL (2.5 mg) of solution to a total of 3 mL with NS; also compatible with cromolyn or ipratropium nebulizer solutions.

IV [Canadian product]: Dilute 5 mg in 500 ml of NS, D5W, or D5NS for a concentration of 10 mcg/mL. Use within 24 hours.

Preparation for Administration: Pediatric

Solution for nebulization: 0.5% solution: Dilute 0.25 mL (1.25 mg dose) or 0.5 mL (2.5 mg dose) of solution to a total of 3 mL with normal saline; also compatible with cromolyn or ipratropium nebulizer solutions

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to open the airways in lung diseases where spasm may cause breathing problems.

• It is used to prevent exercise-induced breathing problems.

Frequently reported side effects of this drug

• Nausea

• Vomiting

• Tremor

• Sore throat

• Back pain

• Aches

• Pains

• Runny nose

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Low potassium like muscle pain or weakness, muscle cramps, or an abnormal heartbeat

• Severe pulmonary disorder like lung or breathing problems like trouble breathing, shortness of breath, or a cough that is new or worse

• Chest pain

• Abnormal heartbeat

• Fast heartbeat

• Severe anxiety

• Severe headache

• Severe dizziness

• Passing out

• Vision changes

• Stevens-Johnson syndrome/toxic epidermal necrolysis like red, swollen, blistered, or peeling skin (with or without fever); red or irritated eyes; or sores in mouth, throat, nose, or eyes

• Painful urination

• Trouble urinating

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Contraindications

Hypersensitivity to albuterol or any component of the formulation; severe hypersensitivity to milk proteins (dry powder inhalers).

Documentation of allergenic cross reactivity for sympathomimetics is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Canadian labeling: Additional contraindications (not in US labeling):

Injection: Ventolin: Hypersensitivity to albuterol or any component of the formulation; tachyarrhythmias; risk of abortion during first or second trimester

Inhalation: Tocolytic use in patients at risk of premature labor or threatened abortion

Warnings/Precautions

Concerns related to adverse effects:

• Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents (may be fatal); this should be distinguished from inadequate response.

• Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm, oropharyngeal edema), including anaphylaxis, have been reported.

Disease-related concerns:

• Asthma: Albuterol is a short-acting beta₂-agonist that should be used as needed for quick relief of asthma symptoms. Based on a step-wise treatment approach using asthma guidelines, monotherapy without concurrent use of a long-term controller medication should only be reserved for patients with mild, intermittent forms of asthma without the presence of risk factors (Step 1 and/or exercise-induced) (GINA 2019; NAEPP 2007).

• Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, coronary insufficiency, hypertension, heart failure); beta-agonists may produce ECG changes (flattening of the T wave, prolongation of the QTc interval, ST segment depression) and/or cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta₂-agonists may also increase risk of arrhythmias. In a scientific statement from the American Heart Association, albuterol has been determined to be an agent that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate to major) (AHA [Page 2016]).

• Diabetes: Use with caution in patients with diabetes mellitus; beta₂-agonists may increase serum glucose and aggravate preexisting diabetes and ketoacidosis.

• Glaucoma: Use with caution in patients with glaucoma; may elevate intraocular pressure.

• Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.

• Hypokalemia: Use with caution in patients with hypokalemia; beta₂-agonists may decrease serum potassium.

• Renal impairment: Use with caution in patients with renal impairment.

• Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Pediatric: Oral inhalation: Use spacer for children <5 years of age and consider adding a face mask for infants and children <4 years of age.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.

• Lactose: Dry powder inhalers may contain lactose; hypersensitivity reactions (eg, anaphylaxis, angioedema, pruritus, and rash) have been reported in patients with milk protein allergy.

Other warnings/precautions:

• Appropriate use: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.

• Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use may indicate deterioration of asthma, and treatment must not be delayed. A spacer device or valved holding chamber is recommended when using a metered-dose inhaler.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

Because of its minimal effect on beta₁-receptors and its relatively long duration of action, albuterol is a rational choice in elderly when a beta-agonist is indicated. Elderly patients may find it beneficial to utilize a spacer device when using a metered dose inhaler, and this should be strongly encouraged when the older adult is not self-administering their metered-dose inhaler (eg, long-term care patients). Older patients have been found to have a reduced and delayed response to albuterol (Connolly 1995), and close follow-up on response to therapy should be employed in this population. Elderly patients may be more sensitive to the side effects of beta-agonists (eg, tremor, tachycardia). Oral use should be avoided due to adverse effects.

Warnings: Additional Pediatric Considerations

CNS stimulation, hyperactivity, and insomnia occur more frequently in younger children than in adults. In children receiving oral albuterol therapy, erythema multiforme and Stevens-Johnson syndrome have been reported (rare). Outbreaks of lower respiratory tract colonization and infection have been attributed to contaminated multidose albuterol bottle.

Pregnancy Considerations

Albuterol crosses the placenta (Boulton 1997).

Congenital anomalies (cleft palate, limb defects) have rarely been reported following maternal use during pregnancy. Multiple medications were used in most cases, no specific pattern of defects has been reported, and no relationship to albuterol has been established. The amount of albuterol available systemically following inhalation is significantly less in comparison to oral doses.

Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Albuterol is the preferred short acting beta-agonist when treatment for asthma is needed during pregnancy (ACOG 2008; GINA 2019; NAEPP 2007). If high doses are required during labor and delivery, monitoring of glucose concentrations in the newborn for 24 hours is recommended, especially in preterm infants (GINA 2019).

Albuterol may affect uterine contractility. Maternal pulmonary edema and other adverse events have been reported when albuterol was used for tocolysis. Albuterol is not approved for use as a tocolytic; use caution when needed to treat bronchospasm in pregnant women.

Data collection to monitor pregnancy and infant outcomes following exposure to asthma medications is ongoing. For additional information contact the Mothers To Baby Pregnancy Studies conducted by the Organization of Teratology Information Specialists at 1-877-311-8972 or visit http://mothertobaby.org/pregnancystudies/.

Breast-Feeding Considerations

It is not known if albuterol is present in breast milk.

The amount of albuterol available systemically following inhalation is significantly less in comparison to oral doses. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Women with asthma should be encouraged to breastfeed (GINA 2019). Use of albuterol is generally considered acceptable in breastfeeding women when used in usual doses (WHO 2002).

Briggs' Drugs in Pregnancy & Lactation

• Albuterol

Adverse Reactions

Incidence of adverse effects is dependent upon age of patient, dose, and route of administration. Frequency not always defined.

>10%:

Central nervous system: Excitement (children and adolescents 2 to 14 years: 20%), nervousness (4% to 15%)

Neuromuscular & skeletal: Tremor (≥5% to 38%; frequency increases with age)

Respiratory: Upper respiratory tract infection (≥5% to 21%), rhinitis (5% to 16%), bronchospasm (8% to 15%; exacerbation of underlying pulmonary disease), pharyngitis (14%), exacerbation of asthma (11% to 13%)

1% to 10%:

Cardiovascular: Tachycardia (≤7%), hypertension (1% to 3%), chest pain (<3%), edema (<3%), extrasystoles (<3%), chest discomfort, flushing, palpitations

Central nervous system: Shakiness (children and adolescents 6 to 14 years: 9%), headache (3% to 7%), dizziness (<7%), insomnia (1% to 3%), anxiety (<3%), ataxia (<3%), depression (<3%), drowsiness (<3%), rigors (<3%), voice disorder (<3%), hyperactive behavior (children and adolescents 6 to 14 years: 2%), malaise (2%), pain (2%), migraine (≤2%), emotional lability (1%), fatigue (1%), restlessness, vertigo

Dermatologic: Diaphoresis (<3%), skin rash (<3%), urticaria (≤2%), pallor (children 2 to 6 years: 1%)

Endocrine & metabolic: Increased serum glucose (10%), diabetes mellitus (<3%)

Gastrointestinal: Nausea (2% to 10%), vomiting (3% to 7%), unpleasant taste (inhalation site, 4%), gastroenteritis (3%), increased appetite (children and adolescents 6 to 14 years: 3%), viral gastroenteritis (1% to 3%), diarrhea (<3%), eructation (<3%), flatulence (<3%), glossitis (<3%), xerostomia (<3%), gastrointestinal signs and symptoms (children 2 to 6 years: 2%), dyspepsia (1% to 2%), anorexia (children 2 to 6 years: 1%)

Genitourinary: Urinary tract infection (≤3%), difficulty in micturition

Hematologic & oncologic: Decreased hematocrit (7%), decreased hemoglobin (7%), decreased white blood cell count (4%), lymphadenopathy (3%)

Hepatic: Increased serum ALT (5%), increased serum AST (4%)

Hypersensitivity: Hypersensitivity reaction (3% to 6%)

Infection: Cold symptoms (3%), infection (<3%; skin/appendage: ≤2%)

Local: Application site reaction (HFA inhaler: 6%)

Neuromuscular & skeletal: Muscle cramps (1% to 7%; frequency increases with age), musculoskeletal pain (3% to 5%), back pain (2% to 4%), hyperkinesia (≤4%), leg cramps (<3%)

Ophthalmic: Conjunctivitis (children 2 to 6 years: 1%)

Otic: Otitis media (≤4%), ear disease (<3%), otalgia (<3%), tinnitus (<3%)

Respiratory: Throat irritation (10%), viral upper respiratory tract infection (7%), respiratory tract disease (6%), nasopharyngitis (≥5%; children: 2%), oropharyngeal pain (≥5%; children: 2%), sinusitis (≥5%), upper respiratory tract inflammation (5%), cough (≥3%), flu-like symptoms (3%), dyspnea (<3%), laryngitis (<3%), oropharyngeal edema (<3%), pulmonary disease (<3%), bronchitis (≥2%), increased bronchial secretions (2%), wheezing (1% to 2%), epistaxis (children and adolescents 6 to 14 years: 1%), nasal congestion (1%), sinus headache (1%)

Miscellaneous: Fever (≥5% to 6%), accidental injury (<3%)

<1%, postmarketing, and/or case reports: Anaphylaxis, angina pectoris, angioedema, atrial fibrillation, dysgeusia, exacerbation of diabetes mellitus, gag reflex, hoarseness, hyperglycemia, hypokalemia, hypotension, irritability, ketoacidosis, lactic acidosis, metabolic acidosis, muscle spasm (children and adolescents 6 to 14 years), mydriasis (children and adolescents 6 to 14 years), oropharyngeal irritation, paradoxical bronchospasm, peripheral vasodilation, stomach pain (children and adolescents 6 to 14 years), supraventricular tachycardia, tongue ulcer, weakness

* See Cautions in AHFS Essentials for additional information.

Toxicology

• Beta Agonists

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists. Risk C: Monitor therapy

AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy

Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. Risk C: Monitor therapy

Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers. Risk C: Monitor therapy

Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists. Risk X: Avoid combination

Betahistine: May diminish the therapeutic effect of Beta2-Agonists. Risk C: Monitor therapy

Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Risk C: Monitor therapy

Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Risk D: Consider therapy modification

Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Risk C: Monitor therapy

Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Risk C: Monitor therapy

Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. Risk C: Monitor therapy

Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Risk D: Consider therapy modification

Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. Risk C: Monitor therapy

Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non-inhaled formulations of loxapine. Risk X: Avoid combination

Methacholine: Beta2-Agonists (Short-Acting) may diminish the therapeutic effect of Methacholine. Management: Hold short-acting beta₂ agonists for 6 hours before methacholine use. Risk D: Consider therapy modification

Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists. Risk C: Monitor therapy

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Risk C: Monitor therapy

Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Risk C: Monitor therapy

Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy

Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists. Risk C: Monitor therapy

Test Interactions

Increased renin (S), increased aldosterone (S)

Genes of Interest

• Beta-2 Receptor
• G Protein-Coupled Receptor Kinase 5

Monitoring Parameters

FEV₁, peak flow, and/or other pulmonary function tests; blood pressure, heart rate; CNS stimulation; serum glucose, serum potassium, serum creatinine; asthma symptoms; arterial or capillary blood gases (if patients condition warrants); lactate (IV formulation) (BTS 2019); continuous ECG monitoring (intravenous formulation).

Advanced Practitioners Physical Assessment/Monitoring

For inpatient care, monitor vital signs at beginning of therapy and periodically throughout. Evaluate effectiveness of therapy (relief of airway obstruction).

Nursing Physical Assessment/Monitoring

Evaluate effectiveness of therapy (relief of airway obstruction). For inpatient care, monitor vital signs and lung sounds prior to and periodically during therapy.

Dosage Forms Considerations

ProAir Digihaler 0.65 g inhaler, ProAir HFA 8.5 g canisters, ProAir RespiClick 0.65 g inhaler, Proventil HFA 6.7 g canisters, and Ventolin HFA 18 g canisters contain 200 inhalations. Ventolin HFA 8 g canisters contain 60 inhalations. The ProAir Digihaler is a digital inhaler which detects, records, and stores inhaler events, including peak inspiratory flow rate, and transmits data to a mobile application for inhaler use information.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Aerosol Powder Breath Activated, Inhalation:

ProAir Digihaler: 90 mcg/actuation (1 ea) [contains lactose monohydrate]

ProAir RespiClick: 90 mcg/actuation (1 ea) [contains milk protein]

Aerosol Solution, Inhalation:

ProAir HFA: 90 mcg/actuation (8.5 g)

Proventil HFA: 90 mcg/actuation (6.7 g)

Ventolin HFA: 90 mcg/actuation (8 g, 18 g)

Generic: 90 mcg/actuation (6.7 g, 8.5 g, 18 g)

Nebulization Solution, Inhalation:

Generic: 0.63 mg/3 mL (3 mL); 0.083% [2.5 mg/3 mL] (3 mL); 0.5% [2.5 mg/0.5 mL] (20 mL)

Nebulization Solution, Inhalation [preservative free]:

Generic: 0.63 mg/3 mL (3 mL); 1.25 mg/3 mL (3 mL); 0.083% [2.5 mg/3 mL] (3 mL); 0.5% [2.5 mg/0.5 mL] (1 ea)

Syrup, Oral:

Generic: 2 mg/5 mL (473 mL)

Tablet, Oral:

Generic: 2 mg, 4 mg

Tablet Extended Release 12 Hour, Oral:

VoSpire ER: 4 mg [DSC] [contains fd&c blue #1 aluminum lake, fd&c yellow #10 aluminum lake]

VoSpire ER: 8 mg [DSC]

Generic: 4 mg, 8 mg

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Aerosol Powder Breath Activated, Inhalation:

Ventolin Diskus: 200 mcg/actuation (1 ea) [contains lactose, milk protein]

Aerosol Solution, Inhalation:

Airomir: 90 mcg/actuation (3.7 g, 6.7 g) [contains alcohol, usp]

Ventolin HFA: 90 mcg/actuation (17 g)

Generic: 100 mcg/actuation (6.7 g); 90 mcg/actuation (1 ea)

Liquid, Oral:

Generic: 0.4 mg/mL (250 mL)

Nebulization Solution, Inhalation:

Ventolin: 0.5% [2.5 mg/0.5 mL] (10 mL)

Ventolin PF: 0.1% (2.5 mL); 0.2% (2.5 mL)

Generic: 0.5 mg/mL (2.5 mL); 1 mg/mL (2.5 mL); 2 mg/mL (2.5 mL); 0.1% (2.5 mL, 50 mL); 0.2% (2.5 mL); 0.5% [2.5 mg/0.5 mL] (10 mL)

Solution, Intravenous:

Ventolin: 1 mg/mL (5 mL)

Tablet, Oral:

Generic: 2 mg [DSC], 4 mg [DSC]

Anatomic Therapeutic Chemical (ATC) Classification

• R03AC02
• R03CC02

Generic Available (US)

May be product dependent

Pricing: US

Aerosol powder (ProAir Digihaler Inhalation)

108 mcg/ACT (per each): $176.00

Aerosol powder (ProAir RespiClick Inhalation)

108 (90 Base) mcg/ACT (per each): $75.02

Aerosol solution (Albuterol Sulfate HFA Inhalation)

108 (90 Base) mcg/ACT (per gram): $8.71

Aerosol solution (ProAir HFA Inhalation)

108 (90 Base) mcg/ACT (per gram): $9.44

Aerosol solution (Proventil HFA Inhalation)

108 (90 Base) mcg/ACT (per gram): $14.28

Aerosol solution (Ventolin HFA Inhalation)

108 (90 Base) mcg/ACT (per gram): $3.31

Nebulization (Albuterol Sulfate Inhalation)

0.63 mg/3 mL (per mL): $0.55 - $0.60

1.25 mg/3 mL (per mL): $0.55 - $0.60

(2.5 MG/3ML) 0.083% (per mL): $0.27 - $0.52

(5 MG/ML) 0.5% (per mL): $2.90

Syrup (Albuterol Sulfate Oral)

2 mg/5 mL (per mL): $0.07 - $0.13

Tablet, 12-hour (Albuterol Sulfate ER Oral)

4 mg (per each): $1.78

8 mg (per each): $3.34

Tablets (Albuterol Sulfate Oral)

2 mg (per each): $5.87 - $7.05

4 mg (per each): $5.87 - $5.88

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Relaxes bronchial smooth muscle by action on beta₂-receptors with little effect on heart rate.

Pharmacodynamics/Kinetics

Onset of action:

Nebulization solution: ≤5 minutes.

Oral inhalation: DPI: 5.7 minutes (median); MDI: 5.4 to 8.2 minutes (median).

Oral: Immediate release: ≤30 minutes.

Duration of action:

Nebulization solution: 3 to 6 hours.

Oral inhalation: DPI: ~2 hours (median); MDI: ~4 to 6 hours.

Oral: Immediate release: 6 to 8 hours; Extended release: Up to 12 hours.

Protein binding: 10%.

Metabolism: Hepatic to an inactive sulfate.

Half-life elimination:

Oral inhalation: 3.8 to ~5 hours.

Oral: Immediate release: 5 to 6 hours; Extended release: 9.3 hours.

Time to peak, serum:

Nebulization solution: 30 minutes.

Oral inhalation: DPI: 30 minutes; MDI: 25 minutes (mean).

Oral: Immediate release: ≤2 hours; Extended release: 6 hours

Time to peak, FEV₁:

Nebulization solution: ~1 to 2 hours.

Oral inhalation: DPI: Within 30 minutes; MDI: 47 minutes.

Oral: Immediate release: 2 to 3 hours.

Excretion: Urine (80% to 100% [oral inhalation]; 76% over 3 days [60% metabolite; oral]); Feces (<20% [oral inhalation]; 4% [oral]).

Pharmacodynamics/Kinetics: Additional Considerations

Renal function impairment: There was a 67% decline in albuterol clearance in patients with CrCl 7 to 53 mL/minute.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Infrequent occurrence of unpleasant taste, glossitis, sinusitis, and xerostomia (normal salivary flow resumes upon discontinuation) have been reported. Rare occurrence of dysgeusia and tongue ulcers have also been reported.

Effects on Bleeding

No information available to require special precautions

Related Information

• Inhalant Agents
• Oral Medications That Should Not Be Crushed or Altered

Pharmacotherapy Pearls

The 2019 Global Initiative for Asthma (GINA) report, Global Strategy for Asthma Management and Prevention Guidelines, and the 2018 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2018 report do not recommend the use of oral systemic albuterol as a quick-relief medication and do not recommend regularly scheduled daily, chronic use of inhaled beta-agonists for long-term control of asthma or chronic obstructive pulmonary disease, respectively.

Index Terms

AccuNeb; Albuterol Sulfate; Salbutamol; Salbutamol Sulphate; Volmax

FDA Approval Date

May 01, 1981

References

ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. Obstet Gynecol. 2008;111(2 Pt 1):457-464.[PubMed 18238988]

Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319.[PubMed 11487763]

Airomir (salbutamol) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; October 2017.

Albuterol sulfate inhalation solution 0.5% [prescribing information]. Amityville, NY: Hi-Tech Pharmacal Co; February 2017.

Albuterol sulfate inhalation solution 0.083% [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; January 2013.

Albuterol sulfate inhalation solution 0.083% [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; June 2013.

Albuterol sulfate inhalation solution 0.021% and 0.042% [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; January 2013.

Albuterol sulfate syrup [prescribing information]. Largo, FL: VistaPharm, Inc.; June 2016.

Albuterol sulfate syrup [prescribing information]. West Caldwell, NJ: Quagen Pharmaceuticals LLC; September 2019.

Albuterol sulfate tablet [prescribing information]. Langhorne, PA: Virtus Pharmaceuticals USA; August 2018.

Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. 1990;38(5):869-872.[PubMed 2266671]

Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann Intern Med. 1989;110(6):426-429.[PubMed 2919849]

Aronoff GR, Bennett WM, Berns JS, et al, eds. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007.

Ballard J, Lugo RA, and Salyer JW, "A Survey of Albuterol Administration Practices in Intubated Patients in the Neonatal Intensive Care Unit," Respir Care, 2002, 47(1):31-8.[PubMed 11749685]

Bartfield JM, Boenau IB, Lozon J, et al, “Comparison of Metered Dose Inhaler and Oral Administration of Albuterol in the Outpatient Treatment of Infants and Children,” Am J Emerg Med, 1995, 13(3):375-8.[PubMed 7755840]

Batterink J, Cessford TA, Taylor RA. Pharmacological interventions for the acute management of hyperkalemia in adults. Cochrane Database Syst Rev. 2015;10:CD010344. doi: 10.1002/14651858.CD010344.pub2

Bonini M, Di Mambro C, Calderon MA, et al. Beta₂-agonists for exercise-induced asthma. Cochrane Database Syst Rev. 2013;(10):CD003564. doi: 10.1002/14651858.CD003564.pub3.[PubMed 24089311]

Boulton DW, Fawcett JP, and Fiddes TM, "Transplacental Distribution of Salbutamol Enantiomers at Caesarian Section," Br J Clin Pharmacol,1997, 44(6):587-90.[PubMed 9431837]

British Thoracic Society (BTS). BTS/SIGN British guideline on the management of asthma. https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/. Updated 2019. Accessed January 15, 2019.

Campbell RL, Kelso JM. Anaphylaxis: Emergency treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 12, 2019.

Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. [published correction appears in Eur Respir J. 2006;27(1):242]. Eur Respir J. 2004;23(6):932-946.[PubMed 15219010]

Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm.[PubMed 6810084]

COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest. 1994;105(5):1411-1419.[PubMed 8181328]

Connolly MJ, Crowley JJ, Charan NB, Nielson CP, Vestal RE. Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest. 1995;108(2):401-406.[PubMed 7634874]

Fanta CH. Acute exacerbations of asthma in adults: Emergency department and inpatient management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 4, 2019b.

Fanta CH. Acute exacerbations of asthma in adults: Home and office management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 4, 2019a.

Fanta CH. Treatment of intermittent and mild persistent asthma in adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 15, 2019c.

Ferguson GT, Make B. Management of stable chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 5, 2019.

Fok TF, Lam K, Ng PC, et al, "Randomised Crossover Trial of Salbutamol Aerosol Delivered by Metered Dose Inhaler, Jet Nebuliser, and Ultrasonic Nebuliser in Chronic Lung Disease," Arch Dis Child Fetal Neonatal Ed, 1998, 79(2):F100-4.[PubMed 9828734]

Fuhrman B, Zimmerman J, eds. Pediatric Critical Care. 4th ed. Elsevier Health; 2011.

Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/. Updated 2018. Accessed September 30, 2018.

Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Updated 2019. Accessed November 11, 2019.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2018 Report. https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Updated 2018. Accessed November 11, 2019.

Grammer LC. Idiopathic anaphylaxis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 11, 2020.

Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, "Preparing for Pediatric Emergencies: Drugs to Consider," Pediatrics, 2008, 121(2):433-43.[PubMed 18245435]

Hess D. Delivery of inhaled medication in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 4, 2019.

"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Pediatrics. 1997;99(2):268-278.[PubMed 9024461]

Kang SK. Diagnosis and treatment of an acute reaction to a radiologic contrast agent. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 27, 2019.

Katz RW, Kelly HW, Crowley MR, et al, “Safety of Continuous Nebulized Albuterol for Bronchospasm in Infants and Children,” Pediatrics, 1993, 92(5):666-9.[PubMed 8414852]

Kim HJ. Acute therapy for hyperkalemia with the combined regimen of bicarbonate and beta(2)-adrenergic agonist (salbutamol) in chronic renal failure patients. J Korean Med Sci. 1997;12(2):111-116.[PubMed 9170015]

Krebs SE, Flood RG, Peter JR, Gerard JM. Evaluation of a high-dose continuous albuterol protocol for treatment of pediatric asthma in the emergency department. Pediatr Emerg Care. 2013;29(2):191-196.[PubMed 23364383]

Lee H, Kim J, Tagmazyan K. Treatment of stable chronic obstructive pulmonary disease: the GOLD guidelines. Am Fam Physician. 2013;88(10):655-663, 663B-663F.[PubMed 24364481]

Leikin JB, Linowiecki KA, Soglin DF, et al, “Hypokalemia After Pediatric Albuterol Overdose: A Case Series,” Am J Emerg Med, 1994, 12(1):64-6.[PubMed 8285977]

Lemanske RF Jr. Beta agonists in asthma: Acute administration and prophylactic use. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 15, 2019b.

Lemanske RF Jr. Beta agonists in asthma: Controversy regarding chronic use. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 4, 2019a.

Levin DC, Little KS, Laughlin KR, et al. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease. Am J Med. 1996;100(1A):40S-48S.[PubMed 8610716]

Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341-384. doi: 10.1016/j.anai.2015.07.019.[PubMed 26505932]

Mahajan M, Tucker J, and Dolgin J, “Protocol for Management of Accidental Pediatric Albuterol Ingestions,” Vet Hum Toxicol, 1994, 36:361.

Mandelberg A, Krupnik Z, Houri S, et al. Salbutamol metered-dose inhaler with spacer for hyperkalemia: how fast? how safe? Chest. 1999;115(3):617-622.[PubMed 10084465]

McClure RJ, Prasad VK, Brocklebank JT. Treatment of hyperkalaemia using intravenous and nebulised salbutamol. Arch Dis Child. 1994;70(2):126-128.[PubMed 8129434]

Mhanna MJ, Patel JS, Patel S, et al, "The Effects of Racemic Albuterol Versus Levalbuterol in Very Low Birth Weight Infants," Pediatr Pulmonol, 2009, 44(8):778-83.[PubMed 19598281]

Mount DB. Treatment and prevention of hyperkalemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 5, 2019.

Nair S, Thomas E, Pearson SB, Henry MT. A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD. Chest. 2005;128(1):48-54.[PubMed 16002915]

National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf. Accessed June 22, 2015.

O'Byrne PM. Exercise-induced bronchoconstriction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 11, 2020.

O'Callaghan C, Milner AD, and Swarbrick A, “Nebulized Salbutamol Does Have a Protective Effect on Airways in Children Under One Year Old,” Arch Dis Child, 1988, 63(5):479-83.[PubMed 3389861]

Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in Circulation. 2016;134(12):e261]. Circulation. 2016;134(6):e32-e69.[PubMed 27400984]

Papo MC, Frank J, and Thompson AE, “A Prospective, Randomized Study of Continuous Versus Intermittent Nebulized Albuterol for Severe Status Asthmaticus in Children,” Crit Care Med, 1993, 21(10):1479-86.[PubMed 8403956]

Parsons JP, Hallstrand TS, Mastronarde JG, et al; American Thoracic Society Subcommittee on Exercise-induced Bronchoconstriction. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013;187(9): 1016-1027.[PubMed 23634861]

Peters S, McCallister JW. Treatment of moderate persistent asthma in adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 11, 2020.

ProAir Digihaler (albuterol) [prescribing information]. Frazer, PA: Teva Respiratory, LLC; September 2019.

ProAir HFA (albuterol) [prescribing information]. Frazer, PA: Teva Respiratory LLC; June 2019.

ProAir RespiClick (albuterol) [prescribing information]. Horsham, PA: Teva Respiratory; August 2018.

ProAir RespiClick (albuterol) [prescribing information]. Horsham, PA: Teva Respiratory; December 2018.

Proventil HFA (albuterol) [prescribing information]. Whitehouse Station, NJ: Merck & Co Inc; July 2018.

Putcha N, Allon M. Management of hyperkalemia in dialysis patients. Semin Dial. 2007;20(5):431-439.[PubMed 17897250]

Rachelefsky GS and Siegel SC, “Asthma in Infants and Children - Treatment of Childhood Asthma: Part II,” J Allergy Clin Immunol, 1985, 76(3):409-25.[PubMed 2863296]

Schuh S, Parkin P, Rajan A, et al, “High- Versus Low-Dose, Frequently Administered, Nebulized Albuterol in Children With Severe, Acute Asthma,” Pediatrics, 1989, 83(4):513-8.[PubMed 2927990]

Schuh S, Reider MJ, Canny G, et al, “Nebulized Albuterol in Acute Childhood Asthma: Comparison of Two Doses,” Pediatrics, 1990, 86(4):509-13.[PubMed 2216613]

Simons FE, Ardusso LR, Bilò MB, et al; World Allergy Organization. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol. 2011;127(3):587-93.e1-e22. doi: 10.1016/j.jaci.2011.01.038.[PubMed 21377030]

Singh BS, Sadiq HF, Noguchi A, Keenan WJ. Efficacy of albuterol inhalation in treatment of hyperkalemia in premature neonates. J Pediatr. 2002;141(1):16-20.[PubMed 12091845 ]

Spiller HA, Ramoska EA, Henretig FM, et al, “A Two-Year Retrospective Study of Accidental Pediatric Albuterol Ingestions,” Pediatr Emerg Care, 1993, 9(6):338-40.[PubMed 8302698]

Stoller JK. Management of exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 5, 2019.

Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [published corrections appear in Circulation. 2011;123(6)e239; Circulation. 2011;124(15):e405]. Circulation. 2010;122(18)(suppl 3):S829-S861. doi: 10.1161/CIRCULATIONAHA.110.971069[PubMed 20956228]

Ventolin (albuterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2017.

Ventolin Diskus (salbutamol) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; April 2016.

Ventolin HFA inhalation aerosol (salbutamol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline Inc; December 2019.

Ventolin IV infusion solution (salbutamol) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline, Inc; July 2016.

Weiler JM, Brannan JD, Randolph CC, et al. Exercise-induced bronchoconstriction update-2016. J Allergy Clin Immunol. 2016;138(5):1292-1295.[PubMed 27665489]

Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. J Am Soc Nephrol. 1998;9(8):1535-1543.[PubMed 9697678 ]

Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 2008;36(12):3246-3251.[PubMed 18936701 ]

Wenzel S. Treatment of severe asthma in adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 4, 2019.

Wiley JF 2nd, Spiller HA, Krenzelok EP, et al, “Unintentional Albuterol Ingestion in Children,” Pediatr Emerg Care, 1994, 10(4):193-6.[PubMed 7937293]

World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/

Brand Names: International

Aero-Vent (PH); Aerolin (BR, CN, GR, QA); Aeromol (TH); Airmax (CO); Airomir (AU, BE, DK, ES, FI, FR, GB, LU, NO, SE, TW, UY); Asmacaire (PH); Asmadil (BF, BJ, CI, ET, GH, GM, GN, JO, KE, LR, MA, ML, MR, MU, MW, NE, NG, SA, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW); Asmalat (LB); Asmalin Pulmoneb (PH); Asmanol (ZW); Asmatol (AR); Asmavent (ZW); Asmed (ZW); Asmidon (JP); Asmol (SG); Asmol CFC-Free (AU); Assal (MX); Asthalin (IN, LB, LK, NZ, RO, ZW); Asthalin HFA (HK); Asthalin Inhaler (TZ); Asthavent (AE, ZA); Asvimol (PH); Avedox-FC (MX); Bajapres (CO); Bemin (EC); Biomol (MY); Bresaltec (CR, DO, GT, HN, NI, PA, SV); Brodil (BD); Brodil HFA (BD); Broncho-Spray (DE); Broncholin S (EG); Bronchosol (TH); Bronchoterol (EG); Broncolin (MY, PH); Brondisal (ID); Bropil (CL); Brytolin (PH); Butalin (BH, ET, JO, LB, SA); Butamol (AR, AU, PY); Butavent (MY); Buto-Air (ES, MT); Buto-Asma (BG, HK, PK, TH); Butotal (CN); Buventol (AE, AT, CZ, EE, LV, NO, SG, TW); Buventol Easyhaler (TH); Ciplabutol (EC); Cotran (TW); Cybutol (LK); Derihaler (ET, LK); Dipsamol (ID); Durasol CR (LK); Easyhaler Salbutamol (GB, IE); Ecosal (BG, HR); Etinoline (CN); Farcolin (AE, CY, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE); Farmarest (CR, DO, GT, HN, NI, PA, SV); Grafalin (ID); Hivent DS (PH); Huma-Salmol (HU); Inbumed (MX); Lasal Nebu (ID); Lebasma (ET); Libretin (PH); Medolin (SG); Mozal (TW); Nebsal (CR, DO, GT, HN, NI, PA, SV); Neoventil (BH); Respigen (NZ); Sabutal (TW); Salamol (CH, IE, MY); Salapin (MT, NZ); Salbetol (IN); Salbo 2 (LK); Salbron (ID); Salbuair CFC Free (SG); Salbuflo (LK, PH); Salbul (IE); Salbulin (LU); Salbutalan (MX); Salbutamol (HU); Salbutamol-GW (HU); Salbutan (VE); Salbutin (AE, CY, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE); Salbutol (KR); Salbutrim (IL); Salbuvent (PE); Salmaplon (IN); Salmolin (BD); Salomol (TW); Saltam (ID); Solia (TH); Sultanol (AT, DE, JP); Synvent HFA (HK); Teoden (BR); Unibron (MX); Velutine (ID); Venalax (PH); Venderol (SG); Venetlin (JP); Ventamol (ID); Venterol (TH); Venteze (ZA, ZW); Ventilan (CO, PT); Ventilastin (LT, RO); Ventilastin Novolizer (DE, FR); Ventodisk (LU); Ventol (AE, BH, CY, ET, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE); Ventolin (AE, AR, AU, BE, BF, BG, BH, BJ, BS, BZ, CH, CI, CL, CU, CY, CZ, DO, EE, EG, ES, ET, GH, GM, GN, GT, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JM, JO, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PK, PL, PR, PY, QA, RO, RU, SA, SC, SD, SI, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UA, UG, UY, YE, ZM, ZW); Ventolin CFC-Free (AU); Ventolin HFA (BB, BM); Ventoline (DK, FI, FR, NO, SE); Ventylor (UA); Volmax (AE, CY, EC, HU, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE); Zenmolin (AE, CY, HK, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE); Zibil (MX); Zomm (PY)

Last Updated 2/27/20